Journals / Turkish Journal of Medical Sciences / 2012 / Cilt: 42 - Sayı: 1

The effect of omega-3 fatty acid supplementation on plasma orexin A, plasma fatty acids, and anthropometric measurements in patients with narcolepsy

Narkolepsili hastalarda omega-3 yağ asit desteğinin plazma oreksin A, plazma yağ asitleri ve antropometrik ölçümlere etkisi

Pages
77–88
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The data demonstrated that supplementation of n-3 fatty acid did not enhance the plasma orexin A level but did affect some other biochemical parameters.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To determine the effect of omega-3 (n-3) fatty acid supplementation on plasma orexin A, plasma fatty acids, and anthropometric measurements in patients with narcolepsy.
📊
Key Findings & Data:Materials and methods: The study was performed on 17 males with narcolepsy and 14 healthy males between the ages of 21-55.
💡
Conclusion & Impact:Conclusion: The data demonstrated that supplementation of n-3 fatty acid did not enhance the plasma orexin A level but did affect some other biochemical parameters.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Narkolepsi · uyku · oreksin

Abstract

To determine the effect of omega-3 (n-3) fatty acid supplementation on plasma orexin A, plasma fatty acids, and anthropometric measurements in patients with narcolepsy. Materials and methods: The study was performed on 17 males with narcolepsy and 14 healthy males between the ages of 21-55. An n-3 fatty acid supplement of 1.4 g/day was administered to the groups for 2 months. The anthropometric measurements of the individuals were taken at the onset and the end of trial, and orexin, fatty acids, and other biochemical parameters in the plasma were analyzed. Results: While there was no statistically significant change in anthropometric measurements or the other body composition values of the patient group (P > 0.05), there was a statistically significant increase in the body weight, body mass index, waist-to-hip ratio, and body fat mass values (kg, %) of the control group (P < 0.05). There was no difference in the levels of plasma orexin A of the patients within or between groups in the pre- and poststudy measurements (P > 0.05). The poststudy plasma serotonin levels of the patients were lower and plasma insulin levels were higher than in the initial study (P < 0.05). There was a correlation between the plasma orexin A levels and plasma n-3 fatty acids in individuals in the control group at the onset of the study (P < 0.05). Depending on the increase of the fatty acids after the n-3 supplementation, a correlation between plasma orexin A levels and some fatty acids was observed (P < 0.05). Conclusion: The data demonstrated that supplementation of n-3 fatty acid did not enhance the plasma orexin A level but did affect some other biochemical parameters.

Özet

Amaç: Bu çalışmada narkolepsili hastalarda omega-3 (n-3) yağ asit desteğinin plazma oreksin A, plazma yağ asitleri ve antropometrik ölçümlere etkisini saptamak amaçlanmıştır.Yöntem ve gereç: Çalışma, 21-55 yaş arası 31 erkek birey (17 narkolepsili ve 14 sağlıklı) üzerinde yapılmıştır. Gruplara iki ay süresince günlük 1,4 g n-3 yağ asidi desteği verilmiştir. Çalışma başlangıcında ve sonunda bireylerin antropometrik ölçümleri alınmış plazmada oreksin, yağ asitleri ve diğer biyokimyasal parametreler analiz edilmiştir. Bulgular: Çalışma sonunda, hasta grubun antropometrik ölçüm ve diğer vücut bileşim değerlerinde istatistiksel olarak önemli değişiklik yokken (P > 0,05), kontrol grubunun vücut ağırlığı, beden kitle indeksi, bel/kalça oranı, vücut yağ (kg, %) değerlerindeki artış istatistiksel açıdan önemli bulunmuştur (P < 0,05). Hastaların çalışma başı ve sonunda plazma oreksin A düzeylerinde hem grup içi hem de gruplar arasında fark gözlenmemiştir (P > 0,05). Yine hastaların plazma seratonin düzeyleri çalışma başına göre, sonunda azalmış, insülin düzeyleri ise yükselmiştir (P < 0,05). Bireylerin grup içinde plazma n-6/n-3 oranında çalışma sonunda azalma olmasına karşın istatistiksel açıdan önemli değildir (P > 0,05). Plazma n-6/n-3 oranında gruplar arasında ise istatistiksel farklılık görülmüştür (P < 0,05). Kontrol grubundaki bireylerin çalışma başında plazma oreksin A düzeyi ile plazma n-3 yağ asitleri arasında korelasyon görülmüştür (P < 0,05). Yine çalışmada n-3 suplemantasyonu ardından yağ asitlerinin artmasına bağlı olarak plazma oreksin A düzeyi ile bazı yağ asitleri arasında korelasyon gözlenmiştir (P < 0,05). Sonuç: Bu veriler; n-3 yağ asidi desteğinin plazma oreksin A düzeyini yükseltmediğini ancak diğer bazı biyokimyasal parametreleri etkilediğini göstermektedir.

🔖

Cite This Article

GEZMEN, M. K., AKSOY, M. (2022). The effect of omega-3 fatty acid supplementation on plasma orexin A, plasma fatty acids, and anthropometric measurements in patients with narcolepsy. Turkish Journal of Medical Sciences, Cilt: 42 - Sayı: 1, 77–88. https://ajindex.com/articles/611151

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. American Academy of Sleep Medicine. International classifi ca- tion of sleep disorders: diagnostic and coding manual. 2nd ed. Westchester (IL): American Academy of Sleep Medicine; 2005.
  2. Dauvilliers Y, Maret S, Taft i M. Genetics of normal and pathological sleep in humans. Sleep Med Rev 2005; 9: 91-100.
  3. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. Th e epidemiology of narcolepsy. Sleep 2007; 30: 13-26.
  4. Eggermann E, Serafi n M, Bayer L, Machard D, Saint-Mleux B, Jones BE et al. Orexins/hypocretins excite basal forebrain cholinergic neurons. Neuroscience 2001; 108: 177-81.
  5. Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003; 114: 2000-17.
  6. Zeitzer JM, Nishino S, Mignot E. Th e neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol Sci 2006; 27: 368-74.
  7. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-7. Fry JM. Treatment modalities for narcolepsy. Neurology 1998; 50: 43-8.
  8. De Lecea L, Sutcliff e JG. Th e hypocretins and sleep. Th e FEBS Journal 2005; 272: 5675-88.
  9. Lees G, Coyne L. Th e orexins: a novel family of sleep regulating neuropeptides. Curr Anaesth Crit Care 2004; 15: 75-7.
  10. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003; 184: 1010-6.
  11. Beck B, Kozak R, Moar K, Mercer CG. Hypothalamic orexigenic peptides are overexpressed in young Long-Evans rats aft er early life exposure to fat-rich diets. Biochem Biophys Res Commun 2006; 342: 452-8.
  12. Chang G, Karatayev O, Davydova Z, Leibowitz SF. Circulating triglycerides impact on orexigenic peptides and neuronal activity in hypothalamus. Endocrinology 2004; 145: 3904-12.
  13. Shimokawa T, Kumar MV, Lane MD. Eff ect of a fatty acid synthase inhibitor on food intake and wxpression of hypothalamic neuropeptides. Proc Natl Acad Sci USA 2002; 99: 66-71.
  14. Deckelbaum RJ, Worgall TS, Seo T. N-3 fatty acids and gene expression. Am J Clin Nutr 2006; 83: 1520-5.
  15. Delion S, Chalon S, Herault J, Guilloteau E, Besnard JC, Durand G. Chronic dietary alpha-linolenic acid defi ciency alters dopaminergic and serotoninergic neurotransmission in rats. J Nutr 1994; 124: 2466-76.
  16. Wortley KE, Chang GQ, Davydova Z, Leibowitz SF. Pep